U.S. markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.10 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.89 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    -1.49 (-1.83%)
     
  • Gold

    1,668.30
    -0.30 (-0.02%)
     
  • Silver

    19.01
    +0.30 (+1.62%)
     
  • EUR/USD

    0.9801
    -0.0018 (-0.19%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • GBP/USD

    1.1166
    +0.0043 (+0.38%)
     
  • USD/JPY

    144.7200
    +0.2770 (+0.19%)
     
  • BTC-USD

    19,340.21
    +24.46 (+0.13%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Cytokinetics Shares Gain On Positive Data From Heart Disease Candidate

·1 min read
  • Cytokinetics Incorporated (NASDAQ: CYTK) has announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM Phase 2 trial of CK-3773274 (CK-274) in hypertrophic cardiomyopathy (HCM).

  • The Company plans to initiate Phase 3 trial by the end of 2021.

  • Results demonstrated that treatment with CK-274 for ten weeks resulted in statistically significant reductions from baseline compared to placebo in the average resting left ventricular outflow tract pressure gradient (LVOT-G) and the average post-Valsalva LVOT-G.

  • LVOT- G is a predictor of heart failure.

  • 78.6% in Cohort 1 and 92.9% in Cohort 2 achieved the target goal of treatment, defined as resting gradient over 30 mmHg and post-Valsalva gradient over 50 mmHg at Week 10 compared to placebo (7.7%).

  • Reductions in LVOT-G occurred within two weeks of initiating treatment with CK-274, were maximized within two to six weeks, and were sustained until the end of treatment at ten weeks.

  • The observed reductions in LVOT-G were dose-dependent.

  • Treatment with CK-274 was generally well tolerated. The incidence of adverse events was similar between treatment arms. No serious adverse events were attributed to CK-274, and no treatment interruptions occurred on CK-274.

  • Hypertrophic cardiomyopathy (HCM) causes thickening of the heart muscle.

  • Price Action: CYTK shares are up 43% at $27.50 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.